The gene silencing of IRF5 and BLYSS effectively modulates the outcome of experimental lupus nephritis.

ABSTRACT: Systemic lupus erythematosus is a highly complex and heterogeneous autoimmune disease mostly mediated by B cells. It is characterized by circulating self-reactive antibodies that deposit and form immune complexes in kidney, leading to irreparable tissue damage and resulting in lupus nephritis. In a New Zealand Black X New Zealand White F1 mouse model, we tested two different small interfering RNA (siRNA) silencing treatments against interferon regulatory factor 5 (IRF5) and B cell-activating factor (BLYSS) expression and their combination in a second set of animals. The administration of these two siRNAs separately prevented the progression of proteinuria and albuminuria at similar levels to that in cyclophosphamide animals. These treatments effectively resulted in a reduction of serum ant

SUBMITTER: Guiteras J 

PROVIDER: S-EPMC8105598 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature